Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
8/10
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
8/10
AZD-7594, also known as AZ13189620, is an inhaled selective glucocorticoid receptor (GCCR) modulator. AZD-7594 is in phase II clinical trials by AstraZeneca for the treatment of mild to moderate asthma. It is also in phase I clinical trials for the treatment of chronic obstructive pulmonary disorder (COPD).
Shanghai Caerulum Pharma Discovery is the manufacturer of APIs and intermediates of some of the latest compounds in the market. Our focus is on cancer, diabetes and other therapeutic areas.
Shanghai Caerulum Pharma Discovery (CPD) offers high quality and reliable chemical products and integrated biological services including:
1) Best offer for existing APIs and intermediates
2) Custom-synthesis APIs and intermediates
3) DMPK
4) Biological screening
5) Drug Safety Evaluation